- Home
- KTB vs GH Comparison
KTB vs GH Comparison
Compare KTB & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTB
- GH
- Stock Information
- Founded
- KTB 2018
- GH 2011
- Country
- KTB United States
- GH United States
- Employees
- KTB N/A
- GH N/A
- Industry
- KTB Apparel
- GH Medical Specialities
- Sector
- KTB Consumer Discretionary
- GH Health Care
- Exchange
- KTB Nasdaq
- GH Nasdaq
- Market Cap
- KTB 4.3B
- GH 4.3B
- IPO Year
- KTB N/A
- GH 2018
- Fundamental
- Price
- KTB $84.07
- GH $37.46
- Analyst Decision
- KTB Buy
- GH Strong Buy
- Analyst Count
- KTB 8
- GH 14
- Target Price
- KTB $90.71
- GH $39.93
- AVG Volume (30 Days)
- KTB 410.0K
- GH 1.8M
- Earning Date
- KTB 02-26-2025
- GH 02-20-2025
- Dividend Yield
- KTB 2.47%
- GH N/A
- EPS Growth
- KTB 17.87
- GH N/A
- EPS
- KTB 4.43
- GH N/A
- Revenue
- KTB $2,578,094,000.00
- GH $692,256,000.00
- Revenue This Year
- KTB $0.90
- GH $32.21
- Revenue Next Year
- KTB $2.96
- GH $16.90
- P/E Ratio
- KTB $18.97
- GH N/A
- Revenue Growth
- KTB N/A
- GH 29.20
- 52 Week Low
- KTB $52.95
- GH $15.81
- 52 Week High
- KTB $94.82
- GH $39.29
- Technical
- Relative Strength Index (RSI)
- KTB 38.99
- GH 66.67
- Support Level
- KTB $83.06
- GH $34.80
- Resistance Level
- KTB $88.30
- GH $37.46
- Average True Range (ATR)
- KTB 1.85
- GH 1.78
- MACD
- KTB -0.17
- GH 0.51
- Stochastic Oscillator
- KTB 19.27
- GH 80.49
About KTB Kontoor Brands Inc.
Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.